CYON... On April 8, 2005, the Company entered into a binding letter of intent with Evolve Oncology, Inc. ("Evolve") (Pink Sheets: "EVON") to effect a merger with Evolve. The Company will be the surviving corporation. Under the proposed merger, the Company would authorize additional shares of common stock to be issued in the transaction, declare a 2.5 for forward stock split, and issue to Evolve's stockholders approximately 20,800,000 newly issued shares of its common stock. Evolve agreed to assume and to pay approximately $115,000 of the Company's liabilities at the closing of the transaction. After the transaction, stockholders of Evolve would own approximately 95% of the total issued and outstanding common stock of the Company.
Evolve is developing products for the treatment of breast cancer, leukemia and multiple cancer treatments including lymphomas, melanomas and gastric cancer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
CYTATION CORPORATION
By:
/s/ Richard Fisher
Richard Fisher
Chairman and General Counsel
Date: April 11, 2005
News 
Market Data 
Discover 
